因塞特医疗 INCY 深 沪
已收盘 05-15 16:00:00 美东时间
95.31
-2.320
-2.38%
华盛通- 最 高97.70
- 今 开97.44
- 成交量 164.90万股
- 最 低 94.31
- 昨 收 97.63
- 总市值 190.41亿
- 52周最高 112.29
- 市盈率 静 14.87
- 换手率 0.83%
- 52周最低 63.925
- 委 比 98.58%
- 总股本 2.00亿
- 历史最高 153.15
- 量 比 1.16
- 振 幅 3.47%
- 历史最低 11.76
- 每 手 1
- 风险率 13.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MacroGenics announced the divestiture of its manufacturing operations to Bora Pharmaceuticals, expecting up to $202.5 million in proceeds, which will enhance focus on drug discovery and development. The company also expanded monetization of ZYNYZ royalties with Sagard Healthcare, receiving $60 million, with potential for an additional $20 million. Their ADC pipeline remains on track for key milestones, and cash runway is extended through 2028.
05-13 20:01
Incyte says Opzelura cream sustains disease control through 24 weeks in Phase 3 TRuE-AD4 trial
Incyte says Opzelura cream sustains disease control through 24 weeks in Phase 3 TRuE-AD4 trial Incyte reported final 24-week Phase 3 TRuE-AD4 data for Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis, with results presented at 2026 EADV Symposium. Patients who responded early a
05-07 20:50
MacroGenics expands ZYNYZ royalty deal with Sagard, secures $60M upfront
MacroGenics (NASDAQ: MGNX) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners tied to global sales of its drug ZYNYZ. MacroGenics said it will re...
05-04 20:50
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue increase...
05-03 01:40
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Oppenheimer Maintains Perform on Incyte, Raises Price Target to $90
Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Perform and raises the price target from $84 to $90.
04-30 00:36
财报速睇 | 因塞特医疗 2026财年Q1营收12.73亿美元，同比增长20.9%；归母净利润3.03亿美元，同比增长91.7%
华盛资讯4月29日讯，因塞特医疗公布2026财年Q1业绩，公司Q1营收12.73亿美元，同比增长20.9%，归母净利润3.03亿美元，同比增长91.7%。
04-29 04:20
Incyte受益于PD-1抑制剂强劲需求，一季度业绩超预期
Incyte公布的2026年第一季度财报显示，得益于核心药物及癌症治疗组合的强劲需求，公司业绩超出了华尔街分析师的普遍预期。 财报数据显示，Incyt...
04-28 23:30
Incyte Sees FY2026 Sales $4.770B-$4.940B vs $5.569B Est
Incyte (NASDAQ:INCY) sees FY2026 sales of $4.770 billion-$4.940 billion vs $5.569 billion analyst estimate.
04-28 21:02
